We have released the second part of the interview on the Market Access Insider channel on Youtube. Guillem Lopez Casasnovas, Professor of Economics at Universitat Pompeu Fabra, in Barcelona, Spain.

In Norway, the mini-HTA for intraepidermal nerve fiber density in skin biopsy was released in September 2019. The method was determined as efficient and safe. It was recommended to be introduced as part of the clinical routine in the hospital with a two-year follow-up to get enough data regarding the diagnostic volume and financial aspects.

MTRC has developed three reports on the key market access topics, including innovation funding, health technology assessment and funding frameworks for medical devices. These reports help to understand the relevance of these frameworks to certain types of medical technologies, including orthopedics technologies. This post provides some key facts about the HTA, funding and innovation payment landscape for orthopedics devices in Europe.

On behalf of the Federal Joint Committee (G-BA), the Institute for Quality and Efficiency in Health Care (IQWiG) investigated whether a systematic test of newborns for sickle cell disease (SCD) in Germany would make sense.

MTRC has developed three reports on the key market access topics, including innovation funding, health technology assessment and funding frameworks for medical devices. These reports help to understand the relevance of these frameworks to certain types of medical technologies, including ophthalmology technologies. This post provides some key facts about the HTA, funding and innovation payment landscape for ophthalmology devices in Europe.

In September 2019, Skåne Region released a report for ultrasound in symptoms of the acute scrotum that aimed to understand whether increased ultrasound use could improve the diagnostic of the studied condition. Although no studies investigating the direct benefit of ultrasound in patients with symptoms of acute scrotum were identified, its high precision, sensitivity, and specificity were outlined.

In September 2019, the National Institute for Health and Care Excellence (NICE) published three new interventional procedure guidance (for implant insertion for prominent ears, high-intensity focused ultrasound for glaucoma, and bioprosthetic plug insertion for anal fistula) and five new MedTech innovation briefings (for SuperNO2VA for the relief of upper airway obstruction in people with obstructive sleep apnoea, The V.A.C. Veraflo Therapy system for infected wounds, UroShield for preventing catheter-associated urinary tract infections, InterDry for intertrigo, and Alpha-Stim AID for anxiety).

MTRC has developed three reports on the key market access topics, including innovation funding, health technology assessment and funding frameworks for medical devices. These reports help to understand the relevance of these frameworks to certain types of medical technologies, including neuromodulation technologies. This post provides some key facts about the HTA, funding and innovation payment landscape for neuromodulation devices in Europe.

In mid-September 2019, the report of the project OTCA19, titled “Screening for osteoporosis in the general population” was published on the website of the European Network for HTA (EUnetHTA).

MTRC has developed three reports on the key market access topics, including innovation funding, health technology assessment and funding frameworks for medical devices. These reports help to understand the relevance of these frameworks to certain types of medical technologies, including nephrology and urology technologies. This post provides some key facts about the HTA, funding and innovation payment landscape for nephrology and urology devices in Europe.

In September 2019, the Andalusian Health Technology Assessment Department (AETSA) has released an assessment report regarding the evaluation of PET scan usefulness in non-oncological indications. The performed analysis showed that the quality of available systematic reviews related to the issue is generally low and, in some cases, moderate. The high-quality reviews, which conclude that routine use cannot be recommended, were found only for the indication of cognitive impairment with suspected Alzheimer's disease.